H.C. Wainwright Keeps a Buy Rating on Vascular Biogenics (VBLT)


H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Vascular Biogenics (VBLT) today and set a price target of $3. The company’s shares opened today at $1.10, equals to its 52-week low of $1.10.

Ramakanth observed:

“We reiterate our Buy rating of VBLT and our 12-month price target of $3.00 per share. We derive our price target based on the average of two valuation methods: (1) price-sales multiple analysis applying an 6x multiple to our 2026 sales estimate discounted at 18%; and (2) price-earnings multiple analysis applying an 19x multiple to our 2026 estimated earnings discounted at 18%. (1) clinical; (2) regulatory; (3) commercial; (4) partnership; (5) financial; and (6) intellectual property.”

According to TipRanks.com, Ramakanth is a 2-star analyst with an average return of 0.5% and a 35.1% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Trillium Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Vascular Biogenics with a $3 average price target.

See today’s analyst top recommended stocks >>

Based on Vascular Biogenics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $4.05 million. In comparison, last year the company had a GAAP net loss of $6.54 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Vascular Biogenics Ltd. is in the clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of first-in-class treatments for cancer. It offers different programs for cancer and inflammatory disease patients such as vascular targeting system and Lecinoxoids.

Read More on VBLT:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts